Because we observed that inhibiting Pim1 diminishes osteoclast activity, we asked whether treating a mouse model of prostate cancer cell-associated osteolysis with SGI-1776 can reduce both the prostate cancer-cell proliferation and the osteolytic activity of osteoclasts. Here, PIM1 is linked to prostate cancer.